Thus, in some patients receiving PLK1 inhibitors during cancer treatment, the risk of infection with invading microorganisms may be increased due to the impaired ability of the TLR recognition system to sense and initiate a cytokine response (109). The gene discussed is PLK1; the disease is cancer.